The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials

[1]  W. Busse,et al.  Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study , 2017, The Lancet.

[2]  Stuart J Pocock,et al.  The Primary Outcome Fails - What Next? , 2016, The New England journal of medicine.

[3]  I. Pavord,et al.  Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma , 2016, European Respiratory Journal.

[4]  M. Weatherall,et al.  Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use , 2015, BMJ Open Respiratory Research.

[5]  Charlotte Suppli Ulrik,et al.  Asthma and Adherence to Inhaled Corticosteroids: Current Status and Future Perspectives , 2015, Respiratory Care.

[6]  Mike Thomas,et al.  Why asthma still kills: the National Review of Asthma Deaths (NRAD)Confidential Enquiry report , 2014 .

[7]  M. Weatherall,et al.  Accuracy of patient self‐report as a measure of inhaled asthma medication use , 2013, Respirology.

[8]  D. Shaw,et al.  Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. , 2013, The Lancet. Respiratory medicine.

[9]  Tonya S. King,et al.  Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. , 2012, JAMA.

[10]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[11]  C. Rand,et al.  Identifying patient‐specific beliefs and behaviours for conversations about adherence in asthma , 2012, Internal medicine journal.

[12]  H. Boushey,et al.  Asthma outcomes: exacerbations. , 2012, The Journal of allergy and clinical immunology.

[13]  E. Burchard,et al.  Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. , 2011, The Journal of allergy and clinical immunology.

[14]  N. Shahidi,et al.  Current recommendations for the treatment of mild asthma , 2010, Journal of asthma and allergy.

[15]  B. Zhang,et al.  Long-acting &bgr;2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD , 2010, European Respiratory Journal.

[16]  I. Adcock,et al.  Rescue treatment in asthma. More than as-needed bronchodilation. , 2009, Chest.

[17]  C. Delacourt,et al.  Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations , 2007, Allergy.

[18]  G. Canonica,et al.  Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. , 2007, The New England journal of medicine.

[19]  T. Haahtela,et al.  Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study , 2006, European Respiratory Journal.

[20]  K. Rabe,et al.  Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study , 2006, The Lancet.

[21]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[22]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[23]  Kevin B Weiss,et al.  Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. , 2004, The Journal of allergy and clinical immunology.

[24]  William W Busse,et al.  Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial , 2003, The Lancet.

[25]  S. Suissa,et al.  Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma , 2002, Thorax.

[26]  A Tattersfield,et al.  Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. , 2001, American journal of respiratory and critical care medicine.

[27]  R. Pauwels,et al.  Low-dose inhaled corticosteroids and the prevention of death from asthma. , 2000, The New England journal of medicine.

[28]  R. Barbour,et al.  The role of qualitative research in broadening the 'evidence base' for clinical practice. , 2000, Journal of evaluation in clinical practice.

[29]  M. Evans,et al.  Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. , 1997 .

[30]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[31]  R. Hancox,et al.  Combination corticosteroid/β-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? , 2014, The Journal of allergy and clinical immunology.

[32]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.